Summary
- Company Announcement Date:
- FDA Publish Date:
- Product Type:
- Drugs
- Reason for Announcement:
- Fluid leakage and low fill volume may cause a lack in sterility
- Company Name:
- B. Braun Medical Inc.
- Brand Name:
- B. Braun Medical Inc.
- Product Description:
- 0.9% Sodium Chloride for Injection USP 250ML in Excel
Company Announcement
B. Braun Medical Inc. (B. Braun) is voluntarily recalling five (5) lots of 0.9% Sodium Chloride for Injection USP 250ML in Excel within the United States to the hospital/user level. The voluntary recall has been initiated due to fluid leakage or low fill volume of the respective containers.
The biggest risk with a slow leak in any intravenous solution preparation is a break in sterility which poses a risk for the patient being exposed to a bacterial or fungal infection. There is a remote probability this could lead to bloodstream infection. B. Braun has not received any reports of adverse events related to this recall.
0.9% Sodium Chloride for Injection USP in Excel is indicated for extracellular fluid replacement, treatment of metabolic alkalosis in the presence of fluid loss and mild sodium depletion. 0.9% Sodium Chloride Injection USP in Excel is also indicated for use as a priming solution in hemodialysis procedures and may be used to initiate and terminate blood transfusions without hemolyzing red blood cells.
| Product Catalog Number: | Lot Number: | NDC: | Product Description: | Distribution Date Range: | Expiration Date: | Region Distributed: |
|---|---|---|---|---|---|---|
| L8002 | ||||||
| J1E086 | 0264-7800-20 | 0.9% NACL INJ USP 250ML | 15JUN2021 – 22JUL2021 | 31-May-23 | United States | |
| J1E204 | 0264-7800-20 | 0.9% NACL INJ USP 250ML | 17JUN2021 – 21JUL2021 | 31-May-23 | United States | |
| J1E213 | 0264-7800-20 | 0.9% NACL INJ USP 250ML | 02JUN2021 – 28JUN2021 | 31-May-23 | United States | |
| J1H137 | 0264-7800-20 | 0.9% NACL INJ USP 250ML | 14JUL2021 – 20OCT2021 | 30-Jun-23 | United States | |
| J1H138 | 0264-7800-20 | 0.9% NACL INJ USP 250ML | 14JUL2021 – 29OCT2021 | 30-Jun-23 | United States |
Product was distributed Nationwide within the United States to domestic distributors.
B. Braun is notifying its distributors and customers by an official recall notice sent via certified registered mail and is arranging for return of all recalled products. Facilities and distributors that have product which is being recalled should discontinue use immediately and contact the B. Braun Medical Inc. Customer Support Department at 800-227-2862 Monday through Friday, 8 a.m. – 6 p.m. EST to arrange for product return.
Facilities with questions regarding this recall can contact B. Braun by phone at 800-227-2862 Monday through Friday, 8 a.m. – 6 p.m. EST. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.
Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.
- Complete and submit the report Online
- Regular Mail or Fax: Download form or call 1- 800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.
Company Contact Information
- Consumers:
- B. Braun
- 800-227-2862
- Media:
- Allison Longenhagen
- 484-523-9801
- allison.longenhagen@bbraunusa.com
I’d must seek advice from you here. Which isn’t some thing It’s my job to do! I spend time reading an article that will make people think. Also, thank you allowing me to comment! buy 4D online in Malaysia
ReplyDeleteIs it just me or does everybody prefer the https version of websites. Like this, how-to-sign-as-power-of-attorney\ work doesn’t have it and I am being paranoid. How big a difference does it make by the way.
ReplyDeleteI can finish my work with just on time, thanks to https://www.airslate.com/product/contract-management. This is the reason I'm satisfied, actually. No cons at all!
ReplyDeleteThe ESIGN Act treats electronic signatures as legally binding as handwritten ones. Laws like ESIGN become practical with the use of technology such as https://www.signnow.com/ask/how-does-the-esign-act-recognize-electronic-contracts-as-equivalent-to-written-contracts. Use robust eSignature capabilities and technologies to maintain efficient business processes.
ReplyDelete